سعر تارسيفا 100مجم 30 قرص 2026
Tarceva 100 mg 30 f.c. tabsمعلومات الدواء
التفاصيل الكاملةعن الدواءAbout the medicine
Erlotinib 100 mg film-coated tablets, pack of 30 (Roche, distributed by Multipharma in Egypt).
Erlotinib 100 mg film-coated tablets, pack of 30 (Roche, distributed by Multipharma in Egypt).
دواعي الاستعمالUses
- Metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations: first-line, maintenance, or after progression following at least one prior chemotherapy regimen.الفئة: AdultsDailyMed (US National Library of Medicine)
- First-line treatment of locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.الفئة: AdultsDailyMed (US National Library of Medicine)
- Metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations: first-line, maintenance, or after progression following at least one prior chemotherapy regimen.Population: AdultsDailyMed (US National Library of Medicine)
- First-line treatment of locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.Population: AdultsDailyMed (US National Library of Medicine)
الآثار الجانبيةSide effects
- Most common (>= 20%): rash, diarrhoea, anorexia, fatigue, dyspnoea, cough, nausea and vomiting.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
- Most common (>= 20%): rash, diarrhoea, anorexia, fatigue, dyspnoea, cough, nausea and vomiting.International label, same formulation · DailyMed (US National Library of Medicine)
موانع الاستعمالContraindications
- None (US label).نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
- None (US label).International label, same formulation · DailyMed (US National Library of Medicine)
تحذيرات واحتياطاتWarnings & precautions
- Interstitial lung disease (1.1%): withhold for new or progressive unexplained pulmonary symptoms; discontinue if ILD is diagnosed.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
- Renal failure and hepatotoxicity (including hepatic failure and hepatorenal syndrome): monitor renal function, electrolytes and liver tests; withhold or discontinue for severe toxicity.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
- Gastrointestinal perforation, bullous/exfoliative skin disorders and corneal perforation or severe ulceration: discontinue.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
- Interstitial lung disease (1.1%): withhold for new or progressive unexplained pulmonary symptoms; discontinue if ILD is diagnosed.International label, same formulation · DailyMed (US National Library of Medicine)
- Renal failure and hepatotoxicity (including hepatic failure and hepatorenal syndrome): monitor renal function, electrolytes and liver tests; withhold or discontinue for severe toxicity.International label, same formulation · DailyMed (US National Library of Medicine)
- Gastrointestinal perforation, bullous/exfoliative skin disorders and corneal perforation or severe ulceration: discontinue.International label, same formulation · DailyMed (US National Library of Medicine)
التداخلات الدوائيةDrug interactions
- Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir, voriconazole, grapefruit) or combined CYP3A4/CYP1A2 inhibitors (e.g. ciprofloxacin)Increase erlotinib exposure; avoid, or reduce the erlotinib dose if co-administration is unavoidable.DailyMed (US National Library of Medicine)
- CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, phenobarbital, St John's wort)Decrease erlotinib exposure; increase the erlotinib dose if co-administration is unavoidable.DailyMed (US National Library of Medicine)
- Cigarette smoking (CYP1A2 induction)Decreases erlotinib exposure; avoid smoking.DailyMed (US National Library of Medicine)
- Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir, voriconazole, grapefruit) or combined CYP3A4/CYP1A2 inhibitors (e.g. ciprofloxacin)Increase erlotinib exposure; avoid, or reduce the erlotinib dose if co-administration is unavoidable.DailyMed (US National Library of Medicine)
- CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, phenobarbital, St John's wort)Decrease erlotinib exposure; increase the erlotinib dose if co-administration is unavoidable.DailyMed (US National Library of Medicine)
- Cigarette smoking (CYP1A2 induction)Decreases erlotinib exposure; avoid smoking.DailyMed (US National Library of Medicine)
الحمل والرضاعةPregnancy & breastfeeding
- Can cause fetal harm based on animal data and mechanism; embryo-fetal lethality and abortion in rabbits at about 3 times human exposure. Advise pregnant women of the risk.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
- No data on presence in human milk; advise not to breastfeed during treatment and for 2 weeks after the final dose.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
- Can cause fetal harm based on animal data and mechanism; embryo-fetal lethality and abortion in rabbits at about 3 times human exposure. Advise pregnant women of the risk.International label, same formulation · DailyMed (US National Library of Medicine)
- No data on presence in human milk; advise not to breastfeed during treatment and for 2 weeks after the final dose.International label, same formulation · DailyMed (US National Library of Medicine)
كيف يعمل الدواءHow it works
- Reversibly inhibits EGFR (HER1) tyrosine kinase activity.
- Erlotinib: Reversibly inhibits EGFR (HER1) tyrosine kinase activity.
أدوية ذات صلة
نفس المادة الفعالة بتركيز آخر
منتجات أخرى من Multipharma
- ارانيسب 10 مكجم 4 سرنجات معبأة للحقنمحلول للحقن في سرنجة معبأة مسبقاً1,383ج.م
- ارانيسب 100مكجم 4 سرنجاتمحلول للحقن في سرنجة معبأة مسبقاً13,587ج.م
- ارانيسب 15 مكجم سرنجة معبأةمحلول للحقن في سرنجة معبأة مسبقاً250ج.م
- Aranesp 20 micrograms solution for injection in pre-filled syringe (1 pre-filled syringe)محلول للحقن في سرنجة معبأة مسبقاً741.75ج.م
- ارانيسب 300 مكجم سرنجة معبأة للحقنمحلول للحقن في سرنجة معبأة مسبقاً9,864ج.م
- بيتميجا 25 مجم 30 قرص ممتد المفعولقرص ممتد المفعول449.5ج.م
من فئة مضاد للأورام
- ابيفيمي 400مجم/16مل فيال للحقنمركز لمحلول للتسريب الوريدي17,081ج.م
- اليمتا 100مجم باودر فيالمسحوق مجفف بالتجميد لتحضير محلول للتسريب الوريدي1,490ج.م
- انسترودكس 1مجم 30 قرصأقراص مغلفة330ج.م
- اناستروزول ساندوز 1مجم 30 قرصأقراص مغلفة495ج.م
- اناستروزول سينثون 1 مجم 28 قرصأقراص مغلفة706ج.م
- انزاتكس 6 مجم / مل فيالمركز لمحلول للتسريب الوريدي (فيال)1,000ج.م
المصادر
- السعر: قوائم أسعار الأدوية المنشورة في مصر.
- DailyMed (US National Library of Medicine)
تعليقات
لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.
أضف تعليقًا